Abstract
Background: Astroglioma, one major form of brain tumors, has remained principally tough to handle for decades, due to the complexity of tumor pathology and the poor response to chemo- and radio-therapies.
Methods: Our previous study demonstrated that nifurtimox could regulate the signaling axis of AKT-GSK3β in various tumor types including the astroglioma U251 cells. Intriguingly, earlier case studies suggested that nifurtimox could possibly permeate the blood brain barrier and arrest neuroblastoma in the brain. These observations jointly encouraged us to explore whether nifurtimox would hinder the growth of astroglioma in vivo.
Results: Our results exhibited that nifurtimox could competently hinder the development of astroglioma in the mouse brain as compared to temozolomide, the first line of drug for brain tumors. Meanwhile the surviving rate, as well as the body-weight was dramatically upregulated upon nifurtimox treatment, as compared to that of temozolomide. These findings offered nifurtimox as a better alternative drug in treating astroglioma in vivo.
Conclusion: Persistently, the manipulation of the signaling axis of AKT-GSK3β in astroglioma was found in line with earlier findings in neuroblastoma when treated with nifurtimox.
Keywords: Astroglioma, Nifurtimox treatment, Temozolomide, in vivo, AKT-GSK3β, blood brain barrier.
Current Molecular Medicine
Title:Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis
Volume: 20 Issue: 9
Author(s): Qiuxia Zhang, Zhenshuai Chen, Wei Yuan, Yu-Qing Tang, Jiangli Zhu, Wentao Wu, Hongguang Ren, Hui Wang, Weiyi Zheng, Zhongjian Zhang*Eryan Kong*
Affiliation:
- Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang,China
- Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang,China
Keywords: Astroglioma, Nifurtimox treatment, Temozolomide, in vivo, AKT-GSK3β, blood brain barrier.
Abstract:
Background: Astroglioma, one major form of brain tumors, has remained principally tough to handle for decades, due to the complexity of tumor pathology and the poor response to chemo- and radio-therapies.
Methods: Our previous study demonstrated that nifurtimox could regulate the signaling axis of AKT-GSK3β in various tumor types including the astroglioma U251 cells. Intriguingly, earlier case studies suggested that nifurtimox could possibly permeate the blood brain barrier and arrest neuroblastoma in the brain. These observations jointly encouraged us to explore whether nifurtimox would hinder the growth of astroglioma in vivo.
Results: Our results exhibited that nifurtimox could competently hinder the development of astroglioma in the mouse brain as compared to temozolomide, the first line of drug for brain tumors. Meanwhile the surviving rate, as well as the body-weight was dramatically upregulated upon nifurtimox treatment, as compared to that of temozolomide. These findings offered nifurtimox as a better alternative drug in treating astroglioma in vivo.
Conclusion: Persistently, the manipulation of the signaling axis of AKT-GSK3β in astroglioma was found in line with earlier findings in neuroblastoma when treated with nifurtimox.
Export Options
About this article
Cite this article as:
Zhang Qiuxia , Chen Zhenshuai , Yuan Wei , Tang Yu-Qing, Zhu Jiangli , Wu Wentao , Ren Hongguang , Wang Hui , Zheng Weiyi , Zhang Zhongjian *, Kong Eryan *, Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis, Current Molecular Medicine 2020; 20 (9) . https://dx.doi.org/10.2174/1566524020666200409124258
DOI https://dx.doi.org/10.2174/1566524020666200409124258 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Prion Protein Oligomerization
Current Alzheimer Research Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Oxysterol Derivatives of Cholesterol in Neurodegenerative Disorders
Current Medicinal Chemistry Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Preliminary Study on Major Phenolic Groups, Antioxidant and Cytotoxic Capacity of Tuckeroo (<i>Cupaniopsis Anacardioides</i>) Fruit Extracts
Current Nutraceuticals A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology